Wellmarker Bio is an innovative venture established in 2016 by Professor Jin Dong-hoon, who was the head of the New Drug Development Center at Asan Medical Center in Seoul. Based on the "therapeutic response prediction biomarker" that allows patients to check the therapeutic efficacy of drugs in advance, it is developing products such as colon cancer treatment, which entered phase 1 clinical trials in February 2021, lung cancer treatment, and liver cancer treatment, which is a leading substance optimization. It has been certified by the Ministry of SMEs and Startups as InnoBiz and has been designated as an excellent company in the first half of 2021 by the Ministry of Science and ICT.